Maitri share price
NSE: MAITRIPharma & HealthcarePharmaceutical Retailers
Maitri at a glance
With a market capitalisation of ₹19 Cr, it ranks 3605th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Pharmaceutical Retailers.
Its return on equity was 11.5% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹14 Cr (+136.6% year on year) and net profit ₹0 Cr, on a consolidated basis. Promoters held 63.01% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹19 CrRank 3605 on NSE
- Price to book
- 2.32×FY26
- EPS (TTM)
- ₹0.53to Q4 FY26
- ROE
- 11.5%FY26
- ROCE
- 20.1%FY26
- Debt to equity
- 0.92FY26
- Net profit margin
- 1.8%FY26
- Book value / share
- ₹11.96FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Maitri quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8 Cr | ₹7 Cr | ₹8 Cr | ₹6 Cr | ₹7 Cr | ₹8 Cr | ₹5 Cr | ₹14 Cr |
| Revenue YoY | +121.2% | +124.5% | +29.8% | −6.8% | −9.7% | +5.7% | −39.6% | +136.6% |
| Net profit | ₹0 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr | −₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit YoY | — | — | −533.3% | — | −566.7% | −4.7% | — | — |
| Net margin | 1.9% | 5.9% | −5.1% | −0.3% | −10.0% | 5.3% | 9.0% | 3.4% |
| EPS | ₹0.33 | ₹0.99 | −₹0.89 | −₹0.04 | −₹1.58 | ₹0.93 | ₹0.95 | ₹0.23 |
Maitri financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹20 Cr | ₹13 Cr | ₹19 Cr | ₹29 Cr | — |
| Operating profit | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹1 Cr | — |
| Net profit | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | — |
| EPS (₹) | ₹1.00 | ₹0.00 | −₹1.00 | ₹0.00 | — |
| Cash from operations | −₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | — |
| Total debt | ₹6 Cr | ₹6 Cr | ₹11 Cr | ₹4 Cr | ₹3 Cr |
| Shareholders' equity | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
Maitri shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 63.01% | 63.01% | 63.01% | 63.01% | 63.01% | 63.01% |
| Non-institutions | 36.99% | 36.99% | 36.99% | 36.99% | 36.99% | 36.99% |
Maitri vs peers
The listed Pharma & Healthcare companies nearest to Maitri by market capitalisation.
Ask anything about Maitri
Pivot answers on the live chart with evidence you can check, and tests strategies against MAITRI's own history. Try: “Why has MAITRI moved over the last three months?” · “Backtest a 50-day moving-average crossover on MAITRI over five years” · “Compare MAITRI with HAMPS on margins and valuation”
Frequently asked questions about Maitri
What is the market cap of Maitri?
Maitri's market capitalisation is ₹19 Cr (₹19 Cr) at the 22 Oct 2026 close, ranking 3605th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Maitri?
Return on equity was 11.5% in FY26 and return on capital employed was 20.1% in FY26 (consolidated figures).
Is Maitri a debt-free company?
No. Maitri's debt-to-equity ratio was 0.92 in FY26, with total debt of ₹3 Cr.
What were Maitri's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Maitri reported revenue of ₹14 Cr, +136.6% year on year, and net profit of ₹0 Cr.
What is the shareholding pattern of Maitri?
As of 30 Jun 2026: promoters 63.01%, non-institutions 36.99%.
Who are Maitri's competitors?
The listed Pharma & Healthcare companies closest to Maitri by market cap are Hamps Bio, Rekvina Labs, Adeshwar Medite, Desh Rakshak, Nidan Lab and Vanta Bioscienc.
Is Maitri a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Maitri's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MAITRI against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text